Skip to main content
FIREBRICK PHARMA LIMITED logo

FIREBRICK PHARMA LIMITED — Investor Relations & Filings

Ticker · FRE ISIN · AU0000197352 ASX Manufacturing
Open in API
Filings indexed 282 across all filing types
Latest filing 2026-04-21 Regulatory Filings
Country AU Australia
Listing ASX FRE

About FIREBRICK PHARMA LIMITED

https://firebrickpharma.com/

Firebrick Pharma Limited is a pharmaceutical company focused on developing and commercializing innovative therapies for respiratory viral infections. The company's primary asset is Nasodine® Nasal Spray, a broad-spectrum antiseptic formulation containing povidone-iodine (PVP-I). Nasodine is designed to target the nasal passages, the primary site where respiratory viruses, including those causing the common cold, replicate. By utilizing the established antimicrobial properties of PVP-I, the product aims to reduce viral load and alleviate symptoms at the source of infection. Firebrick Pharma's research and development efforts center on clinical validation and regulatory pathways to establish Nasodine as a first-in-class treatment for viral upper respiratory tract infections. The company focuses on addressing unmet needs in the management of the common cold through evidence-based antiseptic interventions.

Recent filings

Filing Released Lang Actions
Firebrick investor webinar update 1 page 142.2KB
Regulatory Filings Classification · 78% confidence The document is an ASX announcement titled “Firebrick investor webinar update,” informing shareholders of a forthcoming investor webinar, with registration details and background on the company. This is not a financial report, earnings release, capital raising announcement in substance, or investor presentation PDF itself. It serves as a general regulatory announcement to the ASX about an event. It does not announce the publication of a report nor provide substantive financial or management discussion. Therefore, it falls under the fallback category of Regulatory Filings (RNS).
2026-04-21 English
March 2026 Quarterly Activity Report & Appendix 4C 8 pages 305.9KB
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Activity Report' combined with an 'Appendix 4C' cash flow report for Firebrick Pharma Limited. It provides a comprehensive review of quarterly operations, business milestones, and detailed financial data (cash flow statements). This fits the definition of an Interim/Quarterly Report (IR) as it contains substantive financial data and analysis for a period shorter than a full fiscal year. Q3 2026
2026-04-20 English
Notification regarding unquoted securities - FRE 5 pages 16.9KB
Share Issue/Capital Change Classification · 92% confidence The document is an ASX Appendix 3G filing by Firebrick Pharma Limited providing detailed notice of the issue of unquoted equity securities (options), including ASX security codes, issue dates, quantities, and capital structure post-issue. This is a formal notification of new share (option) issuance and thus falls squarely under announcements of share issues/capital changes. Therefore, it should be classified as Share Issue/Capital Change (Code: SHA).
2026-04-19 English
Application for quotation of securities - FRE 6 pages 18.5KB
Share Issue/Capital Change Classification · 82% confidence The document is an ASX Listing Rules form “Appendix 2A – Application for quotation of securities,” detailing a new issue of ordinary shares for quotation on ASX. This is a direct announcement of a share issue/capital change. Therefore, it matches the “Share Issue/Capital Change” category (SHA).
2026-04-16 English
Notification regarding unquoted securities - FRE 6 pages 20.0KB
Share Issue/Capital Change Classification · 95% confidence The document is an ASX Appendix 3G notification detailing the issue of unquoted equity securities (employee incentive options). It is an announcement of new share issuance/capital change rather than a full report, regulatory filing, or buyback. Therefore it falls under the "Share Issue/Capital Change" category (SHA).
2026-04-16 English
Notification regarding unquoted securities - FRE 5 pages 17.0KB
Share Issue/Capital Change Classification · 90% confidence The document is an ASX Appendix 3G form entitled “Notification of issue, conversion or payment up of unquoted equity securities.” It details the issuance of free‐attaching options and changes to the company’s issued capital. This is not a full report but a specific announcement of a share issue/capital change. Therefore, it falls under the “Share Issue/Capital Change” category (Code: SHA).
2026-04-16 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.